Coya Therapeutics (COYA) News Today $4.57 -0.35 (-7.11%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$4.56 -0.01 (-0.22%) As of 05/19/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock COYA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Wall Street Zen Downgrades Coya Therapeutics (NASDAQ:COYA) to SellMay 16, 2026 | americanbankingnews.comCoya Therapeutics secures FDA fast track status for COYA 302May 14, 2026 | finance.yahoo.comCoya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 13, 2026 | americanbankingnews.comCoya Therapeutics Inc COYAMay 12, 2026 | morningstar.comMCoya Therapeutics Establishes $30 Million ATM Equity ProgramMay 12, 2026 | tipranks.comCoya Therapeutics Updates Q1 Results, COYA 302 ProgressMay 12, 2026 | tipranks.comCoya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateMay 12, 2026 | businesswire.comCoya Therapeutics (COYA) Projected to Post Quarterly Earnings on TuesdayMay 10, 2026 | americanbankingnews.comCoya Therapeutics (COYA) Expected to Announce Earnings on TuesdayMay 5, 2026 | marketbeat.comCoya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in ...April 10, 2026 | finance.yahoo.comCoya Therapeutics Announces Leadership Changes and New DirectorApril 2, 2026 | tipranks.comCoya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy RatingMarch 23, 2026 | tipranks.comCoya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for ...March 18, 2026 | finance.yahoo.comPlus Therapeutics (PSTV) Gets a Buy from Lake StreetMarch 6, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Brookdale Senior Living (BKD) and Coya Therapeutics, Inc. (COYA)February 21, 2026 | theglobeandmail.comCoya Therapeutics to sell 2.522M shares at $4.40 in private placementJanuary 31, 2026 | finance.yahoo.comCoya Therapeutics Announces $11.1 Million Private PlacementJanuary 30, 2026 | businesswire.comCoya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to StockholdersJanuary 20, 2026 | businesswire.comCOYA-302: De-Risked Treg Platform With Compelling FTD Data and ALS Phase 2 Catalyst Supporting Buy RatingJanuary 9, 2026 | tipranks.comCoya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia ...January 8, 2026 | finance.yahoo.comCoya Therapeutics: Early COYA 302 Validation, Regulatory De-Risking, and Upcoming Catalysts Support Buy RatingJanuary 8, 2026 | tipranks.comCoya Therapeutics Reports Positive Frontotemporal Dementia Study DataJanuary 8, 2026 | tipranks.comCoya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)January 5, 2026 | finance.yahoo.comCoya announces Health Canada acceptance of COYA 302 clinical trial applicationDecember 23, 2025 | msn.comCoya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral ...December 23, 2025 | finance.yahoo.comD Boral Capital maintains Coya Therapeutics (COYA) buy recommendationDecember 10, 2025 | msn.comCoya Therapeutics, Inc.: Promising Advancements in ALS and FTD Treatment with COYA-302December 10, 2025 | tipranks.comCoya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALSDecember 9, 2025 | finance.yahoo.comReAlta Life Sciences Designates Dr. Howard Berman as Executive ChairmanDecember 2, 2025 | finance.yahoo.comCoya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials ConferencesNovember 25, 2025 | finance.yahoo.comCoya Therapeutics hopes for ALS Treg approval on Phase II trialNovember 21, 2025 | msn.comBTIG Maintains Coya Therapeutics (COYA) Buy RecommendationNovember 14, 2025 | msn.comCoya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate UpdateNovember 12, 2025 | finance.yahoo.comCoya Therapeutics Reports Q3 2025 Financial ResultsNovember 12, 2025 | tipranks.comCoya Therapeutics price target raised to $17 from $16 at Lake StreetNovember 5, 2025 | msn.comCoya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In VivoNovember 4, 2025 | finance.yahoo.comCoya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In VivoNovember 4, 2025 | businesswire.comCoya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional SharesOctober 28, 2025 | finance.yahoo.comHere’s Greenlight Capital’s Update on Coya Therapeutics (COYA)October 28, 2025 | msn.comCoya Therapeutics’ Promising ALS Study: A Potential Game-Changer?October 27, 2025 | tipranks.comCoya Therapeutics stock falls after pricing $20 million public offeringOctober 24, 2025 | za.investing.comCoya Therapeutics (COYA) Valuation in Focus After Follow-On Equity Offering AnnouncedOctober 24, 2025 | finance.yahoo.comCoya Therapeutics Shares Fall After Stock Offering DisclosureOctober 24, 2025 | marketwatch.comCoya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common StockOctober 24, 2025 | businesswire.comCoya Therapeutics Announces Proposed Public Offering of Common StockOctober 23, 2025 | businesswire.comCoya Therapeutics jumps as Greenlight discusses in Q3 letterOctober 14, 2025 | msn.comCoya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune ...October 7, 2025 | finance.yahoo.comBTIG Reiterates Coya Therapeutics (COYA) Buy RecommendationOctober 1, 2025 | msn.comCORE Public Relations Wins Platinum Pinnacle Awards for Healthcare and Technology PR CampaignsSeptember 30, 2025 | markets.businessinsider.comCoya completes FTD combination therapy trial enrolmentSeptember 30, 2025 | finance.yahoo.com Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COYA Media Mentions By Week COYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COYA News Sentiment▼0.450.38▲Average Medical News Sentiment COYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COYA Articles This Week▼73▲COYA Articles Average Week Get the Latest News and Ratings for COYA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Coya Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Rocket Pharmaceuticals News Today SNDL News Today Ovid Therapeutics News Today Opus Genetics News Today Puma Biotechnology News Today Forte Biosciences News Today C4 Therapeutics News Today DiaMedica Therapeutics News Today Neumora Therapeutics News Today Silence Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COYA) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
